Revelation Biosciences (REVB) Enterprise Value (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Enterprise Value of -$10.7 million for Q4 2025, down 64.64% year-over-year from -$30.3 million in Q4 2024, and up 15.8% quarter-over-quarter from -$12.7 million in Q3 2025.
Revelation Biosciences (REVB) Enterprise Value (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Enterprise Value for 6 consecutive years, with -$10.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value fell 64.64% year-over-year to -$10.7 million; the TTM figure through Dec 2025 stood at -$10.7 million (down 64.64% YoY), while the FY2025 annual figure was -$10.7 million, down 64.64% from the prior year.
- Enterprise Value climbed to -$10.7 million in Q4 2025 per REVB's latest filing, from -$12.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$19749.0 in Q3 2021 and bottomed at -$17.7 million in Q1 2023.
- Historically, Enterprise Value has averaged -$7.8 million across 5 years, with a median of -$6.5 million in 2024.
- Annual changes were most pronounced in 2021 — Enterprise Value soared 99.41% — and 2022, when it tumbled 31270.94%.
- Revelation Biosciences' Enterprise Value stood at -$1.3 million in 2021, then plunged by 312.09% to -$5.3 million in 2022, then tumbled by 128.28% to -$12.0 million in 2023, then soared by 45.8% to -$6.5 million in 2024, then sank by 64.64% to -$10.7 million in 2025.
- Business Quant data shows REVB's Enterprise Value at -$10.7 million in Q4 2025, -$12.7 million in Q3 2025, and -$5.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Revelation Biosciences | 4.14 Mn | -7.36 Mn | - | -11.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.50 Mn |
| Dec 31, 2025 | -10.70 Mn |
| Sep 30, 2025 | -12.71 Mn |
| Jun 30, 2025 | -5.20 Mn |
| Mar 31, 2025 | -3.70 Mn |
| Dec 31, 2024 | -6.50 Mn |
| Sep 30, 2024 | -6.50 Mn |
| Jun 30, 2024 | -12.10 Mn |
| Mar 31, 2024 | -14.55 Mn |
| Dec 31, 2023 | -11.99 Mn |
| Sep 30, 2023 | -13.99 Mn |
| Jun 30, 2023 | -15.70 Mn |
| Mar 31, 2023 | -17.70 Mn |
| Dec 31, 2022 | -5.25 Mn |
| Sep 30, 2022 | -6.20 Mn |
| Jun 30, 2022 | -3.50 Mn |
| Mar 31, 2022 | -7.20 Mn |
| Dec 31, 2021 | -1.27 Mn |
| Sep 30, 2021 | -19,749.00 |
| Jun 30, 2021 | -301,716.00 |